Sagimet Biosciences Inc. (SGMT): R&D Expense
$39.05M
Year ended 2025-12-31
$41.60M
Trailing 12 months to 2026-09-30
+16.2%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $39.05M | +1.6% | 2026-03-11, From 2025-01-01 |
| 2024-12-31 | $38.44M | +94.4% | 2026-03-11, From 2024-01-01 |
| 2023-12-31 | $19.78M | -20.6% | 2025-03-12, From 2023-01-01 |
| 2022-12-31 | $24.92M | n/a | 2024-03-25, From 2022-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Sagimet Biosciences Inc. (SGMT) | 2025-12-31 | $39.05M | +1.6% |
| Avalo Therapeutics, Inc. (AVTX) | 2025-12-31 | $50.08M | +105.0% |
| PMV Pharmaceuticals, Inc. (PMVP) | 2025-12-31 | $69.88M | +19.4% |
| Aardvark Therapeutics, Inc. (AARD) | 2025-12-31 | $48.94M | +181.8% |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $38.20M | -1.6% |
| Filana Therapeutics, Inc. (FLNA) | 2025-12-31 | $26.59M | -61.8% |
| Milestone Pharmaceuticals Inc. (MIST) | 2025-12-31 | $18.11M | +26.1% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $65.58M | +3.0% |
| Kyntra Bio, Inc. (KYNB) | 2025-12-31 | $23.52M | -75.4% |
Compare SGMT, AVTX, PMVP, AARD side by side · Screen every company in Pharmaceutical Preparations ↗